Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments
Company Announcements

Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments

Vir Biotechnology ( (VIR) ) has provided an update.

Vir Biotechnology has finalized an exclusive global licensing deal with Sanofi for three potential clinical-stage T-cell engagers and a protease-cleavable masking platform to bolster its oncology and infectious disease treatment portfolio. Vir made an initial payment of $100 million to Sanofi, with future payments that could total over $1.8 billion, plus royalties on sales. The deal, which passed antitrust scrutiny, also brings key Sanofi employees with specialized expertise to Vir. Concurrently, Vir appointed Jason O’Byrne as its new CFO, and Brent Sabatini as the principal accounting officer, strengthening its executive team.

Learn more about VIR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyVir Biotechnology participates in a conference call with JPMorgan
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyVir Biotechnology price target lowered to $26 from $28 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App